Table 1 US (table summarises published studies on US in screening, including study design, quality features, and results)
From: New technologies in screening for breast cancer: a systematic review of their accuracy
Reference | Objectivea; comparator | Population (mean age in years) | Test evaluated 1 – In consecutive screenees 2 – Independent of comparator | No. of breast cancers (total sample size) | TPR or sensitivity | FPR (based on solid lesions for US) |
|---|---|---|---|---|---|---|
I only; M+CBE Views: ND Reader: 1–2 | Dense breasts and normal M+CBE (54.7) | 1–Yes 2–ND for all subjects (Yes for M-negative/US-positive group) | 145; 124b (13 547 screens in 5418 women) | Incremental TPR of US=25.5% | Incremental FPR of US=2.4% (biopsy) and 5.3% (biopsy or follow-up) | |
I+R; M+CBE Views: 2 Reader: 1 | ‘High-risk’ female relatives of breast cancer patients (48.6) | 1–ND 2–ND | 21 (935) | US: 90.4% M: 52.4% CBE: 33.3% Incremental TPR of US=33.3% | For abnormal screen – biopsy US: 12.9–2.5% M: 6.0–1.6% CBE: 1.8–1.2% Incremental FPR of US=6.9% | |
I + R; M Views and Reader: ND | Moderate-risk (family history) through clinical genetics unit (42) | 1–Yes 2–Yes | 2b (150) | US: 50% M: 50% | US: 6.0% M: 0.7% (core biopsy rate) | |
I+R; M+CBE Views: 2 Reader: 1 | High-risk, BRCA mutation or several family members (43) | 1–ND 2–YES | 6; 5b (186) | US: 60% M: 40% CBE: 20% Incremental TPR of US=0% | US: 7% M: 1% CBE: 1% | |
I+R; M Reader: 1 | Dense breasts and normal CBE (49) | 1–ND 2–ND | 182; 130b (8970) | US: 99% (invasive), 46% (DCIS) M: 73% (invasive), 90% (DCIS) | US: 4% (biopsy) M: ND |
